The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

Luminice-203 yields its first topline data, but where are all the patients?

Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

Pfizer moves to take PF-07934040 into its first clinical trial.

The company defends its cancer strategy, and says it's not a me-too developer.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.